Armata Pharmaceuticals, Inc. 8-K

What Happened
Armata Pharmaceuticals, Inc. (ARMP) announced on March 19, 2026, that it will delay the announcement of its financial results for the fourth quarter and full year ended December 31, 2025. The company filed a Form 8‑K (Regulation FD Disclosure) and furnished a press release with a corporate update related to the delay.

Key Details

• Filing date: March 19, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Period affected: Fourth quarter and full year ended December 31, 2025.
• The press release announcing the delay and providing the corporate update is furnished as Exhibit 99.1 to the 8‑K.
• The 8‑K also includes the interactive Inline XBRL cover page (Exhibit 104).

Why It Matters
A delay in announcing quarterly and full‑year results is material for investors because timely earnings and quarterly results affect valuation, trading decisions, and confidence. Armata’s public notice and press release make the company’s action transparent, but investors should watch for follow‑up filings that provide the rescheduled release date, the actual financial results (revenue, earnings, cash position), and any explanation for the delay.